Jun Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jun Wang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Wei Yu
Department of Biology and Biochemistry, University of Houston, Houston, Texas, USA
9 shared publicationsEun Young Kim
Center for Stem Cell Engineering, Department of Basic Research Laboratories, Texas Heart Institute at St. Luke's Episcopal Hospital, 6770 Bertner Avenue, MC 2-255, Houston, TX 77030, USA
7 shared publicationsIlimbek Beketaev
Center for Stem Cell Engineering, Department of Basic Research Laboratories, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas, USA
5 shared publicationsLi Chen
The Center for Stem Cell Engineering, Texas Heart Institute, Houston, TX 77030, USA; Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA
5 shared publicationsYi Zhang
In Vitro Fertilization Center, Affiliated Hospital of Hainan Medical University, Haikou, Hainan, People's Republic of China
5 shared publications- Jiang Chang
Texas A&M University
4 shared publications
Latest Publications
- 1 January 2016
- Published by Springer Nature
- p. 173-202
Post-translational Modification
- Open Access
- 18 September 2015
- Published by Wiley in Developmental Dynamics
- Vol. 245 (3) , 379-387
cis‐regulatory control of Mesp1 expression by YY1 and SP1 during mouse embryogenesis
Background: Mesp1 is critical for early cardiomyocyte differentiation and heart development. We previously observed down‐regulation of Mesp1 expression in YY1‐ablated mouse embryonic hearts. However, how Mesp1 expression is mediated by YY1 is not well understood. Results: We excised YY1 in the murine embryos using Sox2‐cre and found that Mesp1 was down‐regulated in the embryonic day (E) 7.5 mutant embryos. Also, YY1 activated the 6 kb Mesp1 regulatory element fused to a luciferase reporter. We identified two putative YY1 binding sites in the proximal promoter region of Mesp1 gene, and found that mutation of these sites significantly reduced YY1‐induced activation of the Mesp1 promoter. We also uncovered one cognitive site for SP1, one of the earliest binding partners of YY1 identified. Mutation of this SP1 site repressed SP1‐induced activation of the Mesp1 promoter. Moreover, YY1 and SP1 synergistically activated the Mesp1 promoter. Consistently, while Lacz expression driven by the wild‐type 6 kb regulatory element of Mesp1 gene was robust in E7.5 mouse embryos, the mutation of these binding sites in the context of this 6 kb sequence substantially reduced the LacZ expression during embryogenesis. Conclusions: YY1 and SP1 independently and cooperatively govern the Mesp1 expression during embryogenesis. Developmental Dynamics 245:379–387, 2016.
- 18 September 2015
- Published by Wiley in Developmental Dynamics
- Vol. 245 (3) , 379-387
Open Accesscis‐regulatory control of Mesp1 expression by YY1 and SP1 during mouse embryogenesis
Background: Mesp1 is critical for early cardiomyocyte differentiation and heart development. We previously observed down‐regulation of Mesp1 expression in YY1‐ablated mouse embryonic hearts. However, how Mesp1 expression is mediated by YY1 is not well understood. Results: We excised YY1 in the murine embryos using Sox2‐cre and found that Mesp1 was down‐regulated in the embryonic day (E) 7.5 mutant embryos. Also, YY1 activated the 6 kb Mesp1 regulatory element fused to a luciferase reporter. We identified two putative YY1 binding sites in the proximal promoter region of Mesp1 gene, and found that mutation of these sites significantly reduced YY1‐induced activation of the Mesp1 promoter. We also uncovered one cognitive site for SP1, one of the earliest binding partners of YY1 identified. Mutation of this SP1 site repressed SP1‐induced activation of the Mesp1 promoter. Moreover, YY1 and SP1 synergistically activated the Mesp1 promoter. Consistently, while Lacz expression driven by the wild‐type 6 kb regulatory element of Mesp1 gene was robust in E7.5 mouse embryos, the mutation of these binding sites in the context of this 6 kb sequence substantially reduced the LacZ expression during embryogenesis. Conclusions: YY1 and SP1 independently and cooperatively govern the Mesp1 expression during embryogenesis. Developmental Dynamics 245:379–387, 2016.
- 1 July 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1852 (7) , 1388-1399
Involvement of activated SUMO-2 conjugation in cardiomyopathy
- 1 July 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1852 (7) , 1388-1399
Involvement of activated SUMO-2 conjugation in cardiomyopathy
- Open Access
- 19 February 2015
- Published by Wiley in Developmental Dynamics
- Vol. 244 (5) , 669-680
Critical role of YY1 in cardiac morphogenesis
Background: Yin Yang 1 (YY1), the only DNA binding polycomb group protein, was reported to regulate cardiomyocyte differentiation during early cardiac mesoderm development. However, whether it contributes to cardiac morphogenesis at later developmental stage(s) during embryogenesis is unknown.Results: We excised YY1 in murine hearts during embryogenesis using two temporal‐spatially controlled cre activation approaches, and revealed critical roles of YY1 in cardiac structural formation. Alpha‐myosin heavy chain‐cre (α‐MHC‐cre)‐mediated cardiomyocyte‐specific ablation of YY1 (MHC‐YY1) resulted in perinatal death of mutant mice, and Nkx2.5‐cre‐mediated YY1 null embryos (Nkx2.5‐YY1) died embryonically. In the Nkx2.5‐YY1 mutants, the endocardial cushions (ECs) of both atrioventricular canal (AVC) and outflow tract (OFT) were hypoplastic due to decreased proliferation and increased apoptosis. Endothelial‐to‐mesenchymal transition (EMT) progress was also compromised in ECs. Nkx2.5‐YY1 mutant hearts had normal formation of extracellular matrix, suggesting that the impaired EMT resulted from the direct loss of YY1. We further uncovered that a number of factors that are involved in normal cardiogenesis were downstream targets of YY1.Conclusions: YY1 plays a critical role in cardiac development and occupies a high‐level position within the hierarchy of the cardiac transcriptional network that governs normal cardiogenesis. Developmental Dynamics 244:669–680, 2015.
- 19 February 2015
- Published by Wiley in Developmental Dynamics
- Vol. 244 (5) , 669-680
Open AccessCritical role of YY1 in cardiac morphogenesis
Background: Yin Yang 1 (YY1), the only DNA binding polycomb group protein, was reported to regulate cardiomyocyte differentiation during early cardiac mesoderm development. However, whether it contributes to cardiac morphogenesis at later developmental stage(s) during embryogenesis is unknown.Results: We excised YY1 in murine hearts during embryogenesis using two temporal‐spatially controlled cre activation approaches, and revealed critical roles of YY1 in cardiac structural formation. Alpha‐myosin heavy chain‐cre (α‐MHC‐cre)‐mediated cardiomyocyte‐specific ablation of YY1 (MHC‐YY1) resulted in perinatal death of mutant mice, and Nkx2.5‐cre‐mediated YY1 null embryos (Nkx2.5‐YY1) died embryonically. In the Nkx2.5‐YY1 mutants, the endocardial cushions (ECs) of both atrioventricular canal (AVC) and outflow tract (OFT) were hypoplastic due to decreased proliferation and increased apoptosis. Endothelial‐to‐mesenchymal transition (EMT) progress was also compromised in ECs. Nkx2.5‐YY1 mutant hearts had normal formation of extracellular matrix, suggesting that the impaired EMT resulted from the direct loss of YY1. We further uncovered that a number of factors that are involved in normal cardiogenesis were downstream targets of YY1.Conclusions: YY1 plays a critical role in cardiac development and occupies a high‐level position within the hierarchy of the cardiac transcriptional network that governs normal cardiogenesis. Developmental Dynamics 244:669–680, 2015.
- 1 January 2015
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 78, 154-164
SENP5, a SUMO isopeptidase, induces apoptosis and cardiomyopathy
- 1 January 2015
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 78, 154-164
SENP5, a SUMO isopeptidase, induces apoptosis and cardiomyopathy
- 1 December 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1833 (12) , 2725-2733
Sumoylation regulates nuclear localization and function of zinc finger transcription factor ZIC3
- 1 December 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1833 (12) , 2725-2733
Sumoylation regulates nuclear localization and function of zinc finger transcription factor ZIC3
- 1 March 2012
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 52 (3) , 638-649
Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunction
- 1 March 2012
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 52 (3) , 638-649
Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunction
- Open Access
- 1 February 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (2) , e31005
Conditional Ablation of Ezh2 in Murine Hearts Reveals Its Essential Roles in Endocardial Cushion Formation, Cardiomyocyte Proliferation and Survival
Ezh2 is a histone trimethyltransferase that silences genes mainly via catalyzing trimethylation of histone 3 lysine 27 (H3K27Me3). The role of Ezh2 as a regulator of gene silencing and cell proliferation in cancer development has been extensively investigated; however, its function in heart development during embryonic cardiogenesis has not been well studied. In the present study, we used a genetically modified mouse system in which Ezh2 was specifically ablated in the mouse heart. We identified a wide spectrum of cardiovascular malformations in the Ezh2 mutant mice, which collectively led to perinatal death. In the Ezh2 mutant heart, the endocardial cushions (ECs) were hypoplastic and the endothelial-to-mesenchymal transition (EMT) process was impaired. The hearts of Ezh2 mutant mice also exhibited decreased cardiomyocyte proliferation and increased apoptosis. We further identified that the Hey2 gene, which is important for cardiomyocyte proliferation and cardiac morphogenesis, is a downstream target of Ezh2. The regulation of Hey2 expression by Ezh2 may be independent of Notch signaling activity. Our work defines an indispensible role of the chromatin remodeling factor Ezh2 in normal cardiovascular development.
- 1 February 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (2) , e31005
Open AccessConditional Ablation of Ezh2 in Murine Hearts Reveals Its Essential Roles in Endocardial Cushion Formation, Cardiomyocyte Proliferation and Survival
Ezh2 is a histone trimethyltransferase that silences genes mainly via catalyzing trimethylation of histone 3 lysine 27 (H3K27Me3). The role of Ezh2 as a regulator of gene silencing and cell proliferation in cancer development has been extensively investigated; however, its function in heart development during embryonic cardiogenesis has not been well studied. In the present study, we used a genetically modified mouse system in which Ezh2 was specifically ablated in the mouse heart. We identified a wide spectrum of cardiovascular malformations in the Ezh2 mutant mice, which collectively led to perinatal death. In the Ezh2 mutant heart, the endocardial cushions (ECs) were hypoplastic and the endothelial-to-mesenchymal transition (EMT) process was impaired. The hearts of Ezh2 mutant mice also exhibited decreased cardiomyocyte proliferation and increased apoptosis. We further identified that the Hey2 gene, which is important for cardiomyocyte proliferation and cardiac morphogenesis, is a downstream target of Ezh2. The regulation of Hey2 expression by Ezh2 may be independent of Notch signaling activity. Our work defines an indispensible role of the chromatin remodeling factor Ezh2 in normal cardiovascular development.
- Open Access
- 3 June 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (6) , e20803
Expression of Sumoylation Deficient Nkx2.5 Mutant in Nkx2.5 Haploinsufficient Mice Leads to Congenital Heart Defects
Nkx2.5 is a cardiac specific homeobox gene critical for normal heart development. We previously identified Nkx2.5 as a target of sumoylation, a posttranslational modification implicated in a variety of cellular activities. Sumoylation enhanced Nkx2.5 activity via covalent attachment to the lysine residue 51, the primary SUMO acceptor site. However, how sumoylation regulates the activity of Nkx2.5 in vivo remains unknown. We generated transgenic mice overexpressing sumoylation deficient mutant K51R (conversion of lysine 51 to arginine) specifically in mouse hearts under the control of cardiac α-myosin heavy chain (α-MHC) promoter (K51R-Tg). Expression of the Nkx2.5 mutant transgene in the wild type murine hearts did not result in any overt cardiac phenotype. However, in the presence of Nkx2.5 haploinsufficiency, cardiomyocyte-specific expression of the Nkx2.5 K51R mutant led to congenital heart diseases (CHDs), accompanied with decreased cardiomyocyte proliferation. Also, a number of human CHDs-associated Nkx2.5 mutants exhibited aberrant sumoylation. Our work demonstrates that altered sumoylation status may underlie the development of human CHDs associated with Nkx2.5 mutants.
- 3 June 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (6) , e20803
Open AccessExpression of Sumoylation Deficient Nkx2.5 Mutant in Nkx2.5 Haploinsufficient Mice Leads to Congenital Heart Defects
Nkx2.5 is a cardiac specific homeobox gene critical for normal heart development. We previously identified Nkx2.5 as a target of sumoylation, a posttranslational modification implicated in a variety of cellular activities. Sumoylation enhanced Nkx2.5 activity via covalent attachment to the lysine residue 51, the primary SUMO acceptor site. However, how sumoylation regulates the activity of Nkx2.5 in vivo remains unknown. We generated transgenic mice overexpressing sumoylation deficient mutant K51R (conversion of lysine 51 to arginine) specifically in mouse hearts under the control of cardiac α-myosin heavy chain (α-MHC) promoter (K51R-Tg). Expression of the Nkx2.5 mutant transgene in the wild type murine hearts did not result in any overt cardiac phenotype. However, in the presence of Nkx2.5 haploinsufficiency, cardiomyocyte-specific expression of the Nkx2.5 K51R mutant led to congenital heart diseases (CHDs), accompanied with decreased cardiomyocyte proliferation. Also, a number of human CHDs-associated Nkx2.5 mutants exhibited aberrant sumoylation. Our work demonstrates that altered sumoylation status may underlie the development of human CHDs associated with Nkx2.5 mutants.